Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab Discontinuation in Stable RA (ADMIRE)
NCT00808509Phase 4Completed
- Sponsor
- AbbVie Inc.
- Start
- Jan 2009
- Primary completion
- Sep 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of adalimumab in rheumatoid arthritis (RA) (2 arms), sponsored by AbbVie Inc. Primary endpoint: Percentage of Participants in Remission at 28 weeks. Started Jan 2009; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00808509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00808509.